November 13, 2026 1:02 PM 2 min read
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
by Vandana Singh Benzinga Staff Writer
Follow
ZLABZai Lab Ltd
$24.21-7.01%
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
Reveal Full Score Edge Rankings
Momentum85.05
GrowthN/A
QualityN/A
ValueN/A
Price Trend
ShortMediumLongOverview Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis.
Strong Biomarker Inhibition And Extended Half-Life
Data from 48 healthy volunteers showed that ZL-1503 rapidly and sustainably blocked the IL-13 pathway.
A single dose of 200 mg or higher inhibited phosphorylated STAT6, a key atopic dermatitis signaling biomarker, by at least 90% through Week 12.
The treatment also lowered circulating type 2…